Antibiotic therapy causes loose stools and/or diarrhea quite frequently, probably because of changes in the intestinal fl ora. Super infection arising from the alterations of the normal intestinal fl ora is a factor in the onset of infectious enteritis.
INTRODUCTION
Antibiotic therapy causes loose stools and/or diarrhea quite frequently, probably because of changes in the intestinal fl ora. Super infection arising from the alterations of the normal intestinal fl ora is a factor in the onset of infectious enteritis.
Helicobacter pylori (H pylori) is deeply involved in gastroduodenal ulcer disease and H pylori -positive patients are generally treated with antibiotics to eradicate this bacterium [1] . Triple therapy with a proton pump inhibitor and two antibiotics selected from among the following three: amoxicillin, clarithromycin and metronidazole, is now considered to be the standard therapy, and it is reported that a bacterial eradication rate of about 80-90% can be achieved [2] [3] [4] . Although such therapy causes few serious adverse reactions, gastrointestinal side effects like diarrhea and loose stools occur at a high incidence [5] . It is known that probiotic supplementation prevents or reduces of antibiotics-induced diarrhea. Recent studies have shown that probiotics were effective against gastrointestinal symptoms associated with H pylori eradication therapy [6] . Probiotics are defined as viable microorganisms which, when ingested, have a beneficial effect on human health, including amelioration or prevention of specifi c pathologic conditions [7] . Clostridium butyricum is a butyric acid producing Grampositive anaerobe which is found in soil and the intestines of healthy animals and humans, and the MIYAIRI 588 strain of C. butyricum (CBM) has been used as probiotics for treating and preventing non-antimicrobial induced diarrhea, antimicrobial associated diarrhea and constipation in human beings [8] [9] [10] . MIYA-BM ® tablets (Miyarisan pharmaceutical Co., Ltd., Tokyo, Japan) containing CBM were approved from Japanese Ministry of Health and Welfare for human clinical use since 1970 in Japan.
However, the preventive effect of CBM preparation on the abnormalities of intestinal microflora due to H pylori eradication therapy was unknown. Therefore, in the present study, we have examined the changes of fecal flora and gastrointestinal symptoms frequently during H pylori eradication therapy, and evaluated the utility of CBM supplementation to prevent the disturbance of the intestinal fl ora.
MATERIALS AND METHODS

Patients
Of the patients diagnosed as having gastric or duodenal ulcers at the outpatient clinic of the First Department of Medicine of Chiba University, 35 patients (male/ female: 28/7; mean age 52.7±11.3 years) were enrolled in this study. They were all positive for H pylori by culture method, microscopical examination and the rapid urease test (PyloriTek ® test kit, Serim Research Corp., Elkhart, IN, USA).
The patients were blindly and randomly allocated to two groups. Seventeen patients were assigned the 1 wk triple therapy consisting of amoxicillin 1 500 mg b.i.d., clarithromycin 400 mg b.i.d. and lansoprazole 60 mg b.i.d. (Group 1). Alternatively, eighteen were assigned to the same regimen supplemented with CBM (120 mg t.i.d.), which was started 1 wk prior to the eradication therapy for 14 d (Group 2). The patients had not been treated with any drugs that might have influenced intestinal bacteria, and had no known underlying gastrointestinal disorders. They were all given a full explanation of the contents of the study and they provided their informed consent in writing.
Six weeks after the completion of the therapy, the 13 C-urea breath test was performed to check whether eradication had been achieved.
Collection of stool samples
Stool samples were collected the day before the start of the therapy, and on d 2, 4, 8, 15, and 22 after the start of H pylori eradication therapy in Group 1. In Group 2, stools were also collected 1 wk after the administration of CBM (Figure 1 ). Fresh samples were placed in a transporter fi lled with CO2 (Kenkiporter ® II, Clinical Supply, Gifu, Japan), and were transferred under refrigeration for culture within 24 h of the collection.
Examination of intestinal fl ora
Intestinal flora was investigated according to Mitsuoka' s method [8] . Any bacterium detected was identified at the level of species or genus, and counted. The microorganisms were classifi ed into sub groups of bacteria according to morphology of the colonies, Gram staining and cell shapes. Isolation of Clostridium difficile was also attempted.
The nonselective media used for isolation included TS, EG, and BL agar, while selective media included DHL, TATAC, P, PEES, LBS, NBGT, ES, BS, and CCMA agar. A stool sample (0.5 g) was placed into an anaerobic glove box (N2 80%, H2 10%, CO2 10%) and was diluted with a diluent for anaerobic bacteria from 10-fold to 10 8 -fold in 10 steps. Aliquots (0.05 mL) of each dilution were cultured anaerobically in an incubator in the glove box at 37 ℃ for 3 d. When TS, DHL, TATAC, P, or PEES agar was used the culture plates were removed from the glove box after the bacteria were seeded and were cultured aerobically at 37 ℃ for 1 to 2 d. Any colony that grew during anaerobic culture was also examined for aerobic growth. Smears were prepared on slide glasses for any colony that grew and the smears were subjected to Gram staining for microscopic observation. Then each organism was classified on the basis of its characteristics, including colony morphology, growth under aerobic conditions, and growth in selective culture media. The number of live bacteria of each genus per 1 g of feces was calculated from the number of colonies and converted into a logarithmic equivalent for each bacterial species identified; log colony forming unit/g feces (logCFU/g feces). The detection limit was 2.3 logCFU/g feces. The total count of viable bacteria was calculated from the sum of the counts of each bacterial species. Species in the Enterobacteriaceae were identifi ed by the kit of Enterotube ® Ⅱ (Becton Dickinson, USA).
Assessment of symptoms
Each patient was required to keep a daily record of the conditions of their stools and any abdominal symptoms, from before the therapy to 2 wk after the completion of H pylori eradication therapy.
Statistical analysis
Bacterial counts were expressed as the mean±SD. Statistical evaluation of changes within groups was carried out using the Wilcoxon signed-rank test. The MannWhitney U test was used for comparison between groups. Fisher's exact test was performed to compare the detection rates. Differences of P<0.05 were considered to be statistically signifi cant.
RESULTS
Intestinal fl ora before H pylori eradication therapy
The levels of obligate and facultative anaerobes in the groups did not differ significantly. The predominant bacteria were obligate anaerobes, such as Bacteroidaceae, 
Bifidobacteria and in both groups ( Table 1) . As for the viable counts and detection rates of all species, there was not significant difference between the two groups. The viable counts and detection rates of all species did not change signifi cantly between before and 1 wk after CBM administration in Group 2 (data not shown). None of the patients was positive for C. diffi cile as assessed by culture.
Counts of CBM and detection rate
Counts of CBM increased and averaged 6.7 logCFU/g on the day before eradication therapy. Figure 2 ). The number of facultative anaerobes did not decrease signifi cantly in either group. The detection rates of intestinal flora are shown in 
Clinical symptoms
As for abdominal symptoms, in Group 1, loose stools were noted in 8 of 17 patients (47.1%): diarrhea in 2 of 17 patients (11.8%): abdominal pain and distention in 2 of 17 patients (11.8%), each. In Group 2, loose stools were noted in 4 of 18 patients (22.2%) and diarrhea in 1 of 17 patients (5.6%). The rates were lower in Group 2, although the differences were not signifi cant (Table 3) . Treatment was successful in 13 out of 17 patients in Group 1 (76.5%) and in 17 out of 18 patients in Group 2 (94.4%).
DISCUSSION
The intestinal flora in our subjects before the treatment was similar to that detected in nor mal adults by Mitsuoka [11] . It is known that the normal fecal flora is almost the same as that of the recto-sigmoid colon. Intestinal flora is reported to remain stable in each individual, although it differs among individuals [12] [13] [14] . However, it has been shown that the administration of antimicrobial agents, which are excreted in the bile, in the intestinal mucosa or are incompletely absorbed, causes changes in the normal intestinal fl ora.
Buhling et al. have shown that infrequent detection of Clostridia, Veillonela, Eubacteria, Actinomyces, Bifi dobacteria and E.coli with simultaneous more frequent growth of other Enterobacteria and Yeasts on d 8 of starting H pylori treatment, and after 4 wk of therapy, the microfl ora returned to normal [15] . When they collected stool samples for three times (d 0, 8, 35-40), we examined the chronological changes of the intestinal fl ora were followed 6 or 7 times at short intervals during and after H pylori treatment in this study.
Then we found that the total bacterial counts started to decrease as early as on d 2 of therapy. Especially, obligate anaerobes, which are the dominant bacteria, were markedly reduced. And it took 3 wk for them to return to their pretreatment levels after starting of therapy.
These bacteria are known to produce short-chain fatty acids (SCFA). Such SCFA are considered to promote proliferation of colonic epithelial cells, provide energy for colonic epithelial cells and to stimulate the absorption of water and sodium [16] [17] [18] [19] [20] . Previous studies have demonstrated a close correlation between a decrease in the viable count of anaerobes and a reduction in SCFA content. The drastic reduction of intestinal SCFA associated with the decrease in anaerobes during the diarrheal stage and the increase of the pH thought to be due to these changes, result in increase of the fecal water content [21] [22] [23] . Probiotics are known to prevent or lower the antibioticrelated gastrointestinal side effects. It is reported that CBM together with germinated barley foodstuff effectively increased the level of SCFA in feces and suppressed dextran sulfate sodium-induced experimental colitis in rats [24] . Butyric acids, which is produced by CBM has stronger stimulatory effects on epithelial cell proliferation than other SCFA, such as acetic acid or propionic acid [25] . Tanaka et al. reported that the effect of CBM on the side effect of H pylori eradication triple therapy in vivo [26] . These results have shown that obligate anaerobe and Lactobacillus decreased in the rat intestine and then SCFA in intestinal contents were decreased. However, administration of CBM preparation with H pylori eradication triple therapy was increased SCFA and resident fusiform bacteria in the mucous layer were more frequently observed in rats administered with CBM preparation than H pylori eradication triple therapy.
Our present findings show that CBM preparations prevent the decrease of obligate anaerobes and reduce the frequency of gastrointestinal side effects. These result similar to the pervious in vivo result. However, we did not examine the concentration of SCFA in this study but it is possible that the one of mechanism of action of CBM preparation to prevent the side effect induced by not only maintenance of intestinal flora but also increased SCFA contents by CBM.
In our study, H pylori eradication therapy caused a significantly greater decrease of E.coli , as a results, Enterobacteriaceae, except of E.coli, such as Klebsiella and Enterobacter that are known to potential cause of diarrhea was rising in Group 1.
Our results showed that CBM suppressed the replacement of E.coli by other species in Enterobacteriaceae and superinfection.
In conclusion, intestinal flora with an eradication treatment of H pylori not a little changed. The change was reduced by supplementation of CBM, and the frequency of gastrointestinal side effects decreased. Furthermore CBM may have some beneficial effects on H pylori infection.
